Patients presenting with supratherapeutic loperamide exposure appear to be at high risk for life-threatening dysrhythmias, and close cardiac monitoring should be broadly considered in this population. Management options include appropriate antiarrhythmic and cardiocirculatory support measures.
Bekka et al. (Thu,) studied this question.